Efficacy of oral zinc as an adjuvant in the management of paediatric intractable epilepsy

Efficacy of oral zinc as an adjuvant in the management of paediatric intractable epilepsy:A Randomised controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/089234

Enrollment

Registered

2025-06-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G409- Epilepsy, unspecified

Interventions

Intervention1: ORAL ZINC: Oral zinc For Age Group 1 to 3 years -3 mg/day For Age Group 4 to 8 years-5 mg/day For Age Group 9 to 12 years-8 mg/day Control Intervention1: Conventional Anti Epileptic Dr

Eligibility

Inclusion criteria

Inclusion criteria: All Children between age 1 to 12 years with Intractable Epilepsy Ability of caretaker to record information needed during the period of intervention

Exclusion criteria

Exclusion criteria: 1.Patient on syrup calcium,syrup iron and multivitamin supplementation for last 3 months. 2.Patient whose epilepsy is controlled on anti Epileptic Drug. 3.Known allergy to zinc formulation. 4.patients whose parents do no give consent.

Design outcomes

Primary

Measure	Time frame
To assess the efficacy of oral zinc as an adjuvant in pediatrics intractable epilepsy compared to conventional antiepileptic therapyTimepoint: 6 months	—

Secondary

Measure	Time frame
1.To study the biochemical profile of children with intractable epilepsy 2.To study the adverse effect of zinc, if anyTimepoint: 6 Months	—

Countries

India

Contacts

Public ContactDr. Pranjali Pravin Sheth

Government Medical College, Aurangabad.

kshirsagar.shilpa1974@gmail.com9823078722

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026